Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on juvenile dermatomyositis

L M Pachman1

  • 1Northwestern University Medical School, Chicago, Illinois, USA.

Current Opinion in Rheumatology
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes.

Genes and immunity·2015
Same author

The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis.

Arthritis care and research : the official journal of the Arthritis Health Professions Association·2003
Same author

Juvenile dermatomyositis: the association of the TNF alpha-308A allele and disease chronicity.

Current rheumatology reports·2001
Same author

Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele.

Clinical immunology (Orlando, Fla.)·2001
Same author

TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.

Arthritis and rheumatism·2000
Same author

Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis.

Clinical and diagnostic laboratory immunology·2000
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Juvenile dermatomyositis (JDMS) is a rare autoimmune disease affecting children, showing significant heterogeneity. Research highlights distinct antibody profiles and biomarkers in JDMS, differing from adult forms, impacting disease course and treatment.

Area of Science:

  • Rheumatology
  • Pediatrics
  • Immunology

Background:

  • Juvenile dermatomyositis (JDMS) is a rare systemic vasculopathy causing skin and muscle inflammation.
  • JDMS incidence is over three per million children annually.
  • Previously considered homogeneous, JDMS is now recognized for its heterogeneity, influencing disease progression.

Purpose of the Study:

  • To explore the heterogeneity of Juvenile Dermatomyositis (JDMS).
  • To compare antibody profiles and biomarkers in pediatric JDMS with adult dermatomyositis.
  • To identify distinct indicators of disease activity and endothelial damage in JDMS.

Main Methods:

  • Analysis of myositis-associated antibody (MSA) prevalence in pediatric JDMS patients.
  • Assessment of antinuclear antibody (ANA) positivity in children with JDMS.

Related Experiment Videos

  • Measurement of endothelial cell damage markers (e.g., vWF:Ag), neopterin, and B cell counts in JDMS patients.

    • Main Results:

    • Only about 10% of children with JDMS test positive for known MSAs, contrasting with over 50% in adults.
    • Over 60% of children with JDMS are ANA-positive.
    • The most common MSA in children is anti-Mi-2, unlike adults where tRNA synthetase antibodies are more frequent.
    • Endothelial damage markers (vWF:Ag) are elevated in ~50% of JDMS patients, with others showing elevated neopterin or B cell changes.

    Conclusions:

    • JDMS exhibits significant heterogeneity in antibody profiles and biomarkers.
    • Pediatric JDMS differs from adult dermatomyositis in MSA prevalence and types.
    • Distinct biomarkers indicate varied disease activity and endothelial involvement in JDMS, suggesting different disease subtypes.